ProSciento CEO and leadership

Helge Guenther is ProSciento’s Chief Information Officer. His experience in IT and technology solutions spans more than 20 years, including management of IT operations in highly regulated environments.

Prior to joining ProSciento, Mr. Guenther served as CEO of BIT Group USA and CIO of BIT Group Global, where he oversaw the expansion and optimization of global IT operations. Before that, Mr. Guenther was IT Director at Quest Diagnostics, where he focused on implementing new business solutions in close collaboration with the company’s operations and R&D departments. Prior to his role at Quest Diagnostics, Mr. Guenther was Global Program Manager at Baxter Bioscience, where he oversaw the implementation of Enterprise Resource Planning and related business systems across the company’s locations globally. Mr. Guenther earned his MBA from the University of Duesseldorf, Germany.

Brian Mooney is Chief Operating Officer at ProSciento, Inc. Mr. Mooney is a CRO executive with over 25 years of experience, much of it focused on global expansion of operations for mid to large CROs, including Chiltern, Theorem and Pharmaceutical Research Associates International (PRA). Prior to joining ProSciento, he served as Executive Vice President of Strategic Service Provision at Chiltern, a Covance company, where he oversaw the development and advancement of one of their core business segments.

Before that, Mr. Mooney was Senior Vice President of Clinical Development and General Manager at Theorem Clinical Research (acquired by Chiltern in 2015) and oversaw the expansion and optimization of the clinical operations footprint at a time of rapid momentum for Theorem as a spin out from parent company Omnicare. Prior to his role at Theorem, over a period of 16 years from 1996 to 2012, he held a succession of leadership positions at PRA, including Senior Vice President of Project Services; Vice President of Global Project Management; and Vice President of Countries Group. Over the course of his tenure at PRA, Mr. Mooney contributed significantly to the company’s global expansion of clinical operations, including implementation of PRA’s Global Project Management Methodology initiative and International Partners program. He received his bachelor’s degree in biology with a minor in chemistry from Trenton State College in Trenton, New Jersey.

Stephen Mullennix joined ProSciento has Chief Financial Officer in 2020. Mr. Mullennix has a diverse global finance background consisting of over 25 years of operational and transactional experience in biotech, eco-infrastructure, and private equity sectors and deep experience in corporate growth strategies within highly regulated industries.

Before joining ProSciento, he was Chief Operating Officer and, prior to that, Chief Financial Officer at UroGen Pharma, Ltd.. During his time at UroGen, he helped the company build its management team that successfully launched its first FDA-approved drug for urothelial cancer and completed a $160 million secondary offering. Before his executive leadership role at UroGen, Mr. Mullennix was Chief Financial Officer and Senior Vice President of Operations at SolarReserve, LLC, a solar energy technology company, where he supported the company’s expansion into more than 20 countries and oversaw multiple corporate financings. Prior to SolarReserve, Mr. Mullennix served as a Managing Director at US Renewables Group, a private equity investment fund with more than $750 million of assets under management.

He earned his MBA from the Anderson School at University of California Los Angeles and BA in Economic Geography from Dartmouth College.